Baxter International (NYSE:BAX) Issues Q4 2024 Earnings Guidance

Baxter International (NYSE:BAX - Get Free Report) updated its fourth quarter 2024 earnings guidance on Friday. The company provided earnings per share guidance of 0.770-0.810 for the period, compared to the consensus earnings per share estimate of 0.840. The company issued revenue guidance of -. Baxter International also updated its FY 2024 guidance to 2.900-2.940 EPS.

Baxter International Stock Performance

Shares of Baxter International stock traded down $1.40 on Friday, hitting $34.64. The stock had a trading volume of 6,631,711 shares, compared to its average volume of 4,048,255. The stock has a market cap of $17.67 billion, a price-to-earnings ratio of 7.05, a price-to-earnings-growth ratio of 1.21 and a beta of 0.60. The business's 50 day moving average is $37.50 and its two-hundred day moving average is $36.16. The company has a quick ratio of 0.91, a current ratio of 1.40 and a debt-to-equity ratio of 1.35. Baxter International has a twelve month low of $32.48 and a twelve month high of $44.01.

Baxter International (NYSE:BAX - Get Free Report) last released its quarterly earnings results on Tuesday, August 6th. The medical instruments supplier reported $0.68 EPS for the quarter, beating the consensus estimate of $0.66 by $0.02. Baxter International had a net margin of 16.51% and a return on equity of 18.06%. The business had revenue of $3.81 billion for the quarter, compared to the consensus estimate of $3.75 billion. During the same period in the prior year, the company posted $0.55 earnings per share. Baxter International's revenue was up 2.8% compared to the same quarter last year. Analysts forecast that Baxter International will post 2.96 EPS for the current year.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on the stock. Morgan Stanley cut shares of Baxter International from an "equal weight" rating to an "underweight" rating and dropped their target price for the stock from $39.00 to $30.00 in a report on Monday, July 15th. Wells Fargo & Company dropped their price target on Baxter International from $44.00 to $40.00 and set an "equal weight" rating for the company in a research note on Wednesday, August 7th. The Goldman Sachs Group upped their target price on Baxter International from $36.00 to $40.00 and gave the stock a "neutral" rating in a report on Thursday, August 8th. Citigroup boosted their price target on Baxter International from $38.00 to $40.00 and gave the stock a "neutral" rating in a report on Tuesday, October 1st. Finally, JPMorgan Chase & Co. reduced their target price on shares of Baxter International from $44.00 to $42.00 and set a "neutral" rating on the stock in a report on Wednesday, August 7th. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating and three have assigned a buy rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Hold" and an average price target of $41.20.

Baxter International Company Profile

Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories.